Intercept pharmaceuticals inc.
Intercept Pharmaceuticals, Inc. June 22, 2023 at 5:45 PM · 3 min read Company to discontinue all NASH-related investment and restructure the Company’s operations to strengthen its focus on rare ...
March 6, 2023 at 5:59 AM · 17 min read. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) Q4 2022 Earnings Call Transcript March 2, 2023. Operator: Good day and thank you for standing by. Welcome to ...Net Income/Loss. In the fourth quarter and full year of 2022, Intercept reported a net loss of $20.8 million and net income of $221.8 million, respectively, a decrease compared to a net loss of ...MORRISTOWN, NJ, JULY 1, 2022 – Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on …Mar 10, 2023 · Advisory Committee Meeting scheduled for May 19, 2023. PDUFA Target Action Date is June 22, 2023. MORRISTOWN, N.J., March 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Gastrointestinal Drugs ... Alfasigma S.p.A. today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation, has commenced a cash tender offer to purchase all of the outstanding ...
Nov 7, 2023 · Intercept Pharmaceuticals, Inc.’s mailing address is 305 Madison Avenue, Morristown NJ 07960, United States. They can be reached by phone at 646 747 1000. MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug Administration (FDA) …
01.07.22. LONDON, [July 01], 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, today announced that it has successfully completed the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets ...
Mar 6, 2023 · March 6, 2023 at 5:59 AM · 17 min read. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) Q4 2022 Earnings Call Transcript March 2, 2023. Operator: Good day and thank you for standing by. Welcome to ... Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...Realtime driving directions to Intercept Pharmaceuticals, Inc., 9520 Towne Centre Dr, San Diego, based on live traffic updates and road conditions – from ...
MORRISTOWN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced its financial results for the quarter ended on June 30, 2023.
ICPT: undefined - Stock Price, Quote and News - CNBC
Nareg Sagherian, Executive Director, Global Investor Relations. [email protected]. For media: Karen Preble, Executive Director, Global Corporate Communications. media@interceptpharma ...Intercept Pharmaceuticals, Inc.’s mailing address is 305 Madison Avenue, Morristown NJ 07960, United States. They can be reached by phone at 646 747 1000.Nov 8, 2023 · BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ... We are hosting our first quarter 2022 financial results conference call and webcast on May 6, 2022, at 8:30 a.m. ET. The conference call will be available on the investor page of our website at ...Intercept Pharmaceuticals Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ICPT stock stock was $22.5, which predicted an increase of 18.42%. The lowest target was $14 and the highest was $54. On average, analysts rated ICPT stock stock as a hold.Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”).
MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A.. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.. Following the completion …MORRISTOWN, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced positive topline results from a new interim analysis of its …Tracfone Wireless Inc is one of the leading wireless communication providers in the United States. With a wide range of affordable plans and extensive coverage, Tracfone has garnered a loyal customer base over the years.Our employees are enthusiastic and hard-working individuals who embody our values. Intercept is a biopharmaceutical company working to make a difference in the lives of people living with rare and serious liver diseases. If you are solutions-focused, strive for excellence and want to make an incredible impact on the lives of people living with ... BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s ...MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced an update on the timing of its pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the potential resubmission of its ...
Follow. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...May 26, 2021 · NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has ...
MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financial results on Thursday, April 27, 2023, and provide an update on the commercial launch strategy for ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.November 8, 2023. Bologna, Italy & Morristown, N.J., U.S. – November 8, 2023 – Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of ...Nov 8, 2023 · Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash ... Follow. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug Administration (FDA) …Intercept Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share data) Three Months Ended March 31, 2023 2022 Revenue: Product revenue, net $ 67,958 $ 59,146 Total revenue 67,958 59,146 Operating expenses: Cost of sales 222 223Medical Information. If you are a healthcare professional and have a medical inquiry, visit our Medical Information website. We are INTERCEPT. Our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases.
When it comes to staying informed and up-to-date with the latest news, there are countless options available. One popular choice for many people is Apple News, a news aggregator developed by Apple Inc.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases.
Intercept Pharmaceuticals (NASDAQ:ICPT) is a biopharmaceutical company focused on developing and marketing innovative treatments for progressive liver diseases that are not caused by viruses.Nov 13, 2023 · Medical Information. If you are a healthcare professional and have a medical inquiry, visit our Medical Information website. We are INTERCEPT. Our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases. MORRISTOWN, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to sell to Advanz Pharma, a …To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in …NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the …Bisnis.com, JAKARTA - PT Telkom Indonesia Tbk. terus berusaha membangun infrastruktur telekomunikasi di Ibu Kota Nusantara ( IKN ). Pada tahun ini, …MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...MORRISTOWN, N.J., June 07, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced initial results from a planned interim analysis of its ongoing …Jan 19, 2023 · MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... Intercept Pharmaceuticals, Inc.ICPT announced that the FDA has accepted the company’s new drug application (NDA) for obeticholic acid (OCA) that seeks accelerated approval for the treatment of ...Additional Phase 2 trial of the OCA-bezafibrate combination remains ongoing in Europe. MORRISTOWN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral …
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ...BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical …BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical …Instagram:https://instagram. private race trackbest day of the week to sell stocktdoc tickerwhat is the best bank in tennessee MORRISTOWN, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2022.May 19, 2023 · MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs ... best online stock trading coursescrypto trading robot New data on INT-787, Intercept’s next generation FXR agonist, to be featured in two posters. MORRISTOWN, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a ... 500 to 1 leverage forex Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, an active comparator trial demonstrating the therapeutic ...To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...